2022-04-01 2023-03-31 false Capium Accounts Production 1.1 08261589 bus:FullAccounts 2022-04-01 2023-03-31 08261589 bus:FRS102 2022-04-01 2023-03-31 08261589 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 08261589 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 08261589 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 08261589 2022-04-01 2023-03-31 08261589 2023-03-31 08261589 bus:RegisteredOffice 2022-04-01 2023-03-31 08261589 core:WithinOneYear 2023-03-31 08261589 core:AfterOneYear 2023-03-31 08261589 bus:Director1 2022-04-01 2023-03-31 08261589 bus:Director1 2023-03-31 08261589 bus:Director1 2021-04-01 2022-03-31 08261589 2021-04-01 08261589 bus:CompanySecretary1 2022-04-01 2023-03-31 08261589 bus:LeadAgentIfApplicable 2022-04-01 2023-03-31 08261589 2021-04-01 2022-03-31 08261589 2022-03-31 08261589 core:WithinOneYear 2022-03-31 08261589 core:AfterOneYear 2022-03-31 08261589 bus:EntityAccountantsOrAuditors 2021-04-01 2022-03-31 08261589 core:PlantMachinery 2022-04-01 2023-03-31 08261589 core:PlantMachinery 2023-03-31 08261589 core:PlantMachinery 2022-03-31 08261589 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-03-31 08261589 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2022-03-31 08261589 core:OtherResidualIntangibleAssets 2022-04-01 2023-03-31 08261589 core:OtherResidualIntangibleAssets 2023-03-31 08261589 core:OtherResidualIntangibleAssets 2022-03-31 08261589 core:CostValuation core:Non-currentFinancialInstruments 2023-03-31 08261589 core:CostValuation core:Non-currentFinancialInstruments 2022-03-31 08261589 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-03-31 08261589 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-03-31 08261589 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-03-31 08261589 core:Non-currentFinancialInstruments 2023-03-31 08261589 core:Non-currentFinancialInstruments 2022-03-31 08261589 core:ShareCapital 2023-03-31 08261589 core:ShareCapital 2022-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2023-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2022-03-31 08261589 core:ShareCapitalOrdinaryShares 2022-04-01 08261589 core:ShareCapitalOrdinaryShares 2021-04-01 08261589 core:ShareCapitalOrdinaryShares 2022-04-01 2023-03-31 08261589 core:ShareCapitalOrdinaryShares 2021-04-01 2022-03-31 08261589 core:ShareCapitalOrdinaryShares 2023-03-31 08261589 core:ShareCapitalOrdinaryShares 2022-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2022-04-01 08261589 core:RetainedEarningsAccumulatedLosses 2021-04-01 08261589 core:RetainedEarningsAccumulatedLosses 2022-04-01 2023-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2021-04-01 2022-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2023-03-31 08261589 core:RetainedEarningsAccumulatedLosses 2022-03-31 08261589 dpl:Item1 2022-04-01 08261589 dpl:Item1 2023-03-31 08261589 dpl:Item1 2021-04-01 08261589 dpl:Item1 2022-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 08261589
England and Wales
INDEX MICROBIOLOGY LIMITED
Filleted Unaudited Financial Statements
Period of accounts Start date: 01 April 2022 End date: 31 March 2023

Index Microbiology Limited Contents Page For the year ended 31 March 2023
Company information | 1
Director's report | 2
Accountants' report | 3
Statement of financial position | 4
Notes to the financial statements | 5
Statement of changes in equity | 6

Index Microbiology Limited Company Information For the year ended 31 March 2023
Director | Robert Morley
Registered Number | 08261589
Registered Office | The Churchill Building University Of Bristol Langford Bristol BS40 5DU
Accountants | Bond & Co Chartered Certified Accountants 66 Gloucester Road Bishopston Bristol BS7 8BH
1

Index Microbiology Limited Director's Report For the year ended 31 March 2023
Director's report and financial statements The director presents his/her/their annual report and the financial statements for the year ended 31 March 2023 Principal activities Principal activity of the company during the financial year was that of microbiologists. Director The director who served the company throughout the year was as follows:
Robert Morley
Statement of director's responsibilities The director is responsible for preparing the directors’ report and the financial statements in accordance with applicable law and regulation. Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to select suitable accounting policies and then apply them consistently make judgments and accounting estimates that are reasonable and prudent prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business The director is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. On behalf of the board.
---------------------------------- Robert Morley Director
Date approved: 04 October 2023 2

Index Microbiology Limited Accountants' Report For the year ended 31 March 2023
Bond & Co Chartered Certified AccountantsChartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of Index Microbiology Limited for the year ended 31 March 2023 In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Index Microbiology Limited for the year ended 31 March 2023 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the companys accounting records and from information and explanations you have given us. As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance This report is made solely to the Board of Directors of Index Microbiology Limited , as a body, in accordance with the terms of our engagement letter 09 December 2019. Our work has been undertaken solely to prepare for your approval the accounts of Index Microbiology Limited and state those matters that we have agreed to state to the Board of Directors of Index Microbiology Limited , as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Index Microbiology Limited and its Board of Directors as a body for our work or for this report. It is your duty to ensure that Index Microbiology Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Index Microbiology Limited . You consider that Index Microbiology Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the accounts of Index Microbiology Limited . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts 31 March 2023 Bond & Co Chartered Certified Accountants 66 Gloucester Road Bishopston Bristol BS7 8BH 04 October 2023 3

Index Microbiology Limited Statement of Financial Position As at 31 March 2023
| Notes | 2023 £ |  | 2022 £
--- | --- | --- | --- | ---
Fixed assets |  |  |
Intangible fixed assets | 3 | 3,343 |  | 4,458
Tangible fixed assets | 4 | 14,940 |  | 11,655
|  | 18,283 |  | 16,113
Current assets |  |  |
Debtors | 5 | 85,056 |  | 75,937
Cash at bank and in hand |  | 40,124 |  | 20,274
|  | 125,180 |  | 96,211
Creditors: amount falling due within one year | 6 | (59,632) |  | (49,049)
Net current assets |  | 65,548 |  | 47,162
Total assets less current liabilities |  | 83,831 |  | 63,275
Creditors: amount falling due after more than one year | 7 | (7,539) |  | (10,536)
Provisions for liabilities | 8 | (2,839) |  | (3,062)
Net assets |  | 73,453 |  | 49,677
Capital and reserves |  |  |
Called up share capital |  | 1,000 |  | 1,000
Profit and loss account |  | 72,453 |  | 48,677
Shareholder's funds |  | 73,453 |  | 49,677
For the year ended 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of Part 15 of the Companies Act 2006. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies. The financial statements were approved by the director on 04 October 2023 and were signed by:
------------------------------- Robert Morley Director
4

Index Microbiology Limited Statement of Changes in Equity For the year ended 31 March 2023
|  | Equity share capital |  | Retained Earnings |  | Total
| £ |  | £ |  | £ |
At 01 April 2021 |  | 1,000 |  | 22,327 |  | 23,327
Profit for the year |  |  |  | 36,350 |  | 36,350
Total comprehensive income for the year |  | - |  | 36,350 |  | 36,350
Dividends |  |  |  | (10,000) |  | (10,000)
Total investments by and distributions to owners |  | - |  | (10,000) |  | (10,000)
At 31 March 2022 |  | 1,000 |  | 48,677 |  | 49,677
At 01 April 2022 |  | 1,000 |  | 48,677 |  | 49,677
Profit for the year |  |  |  | 61,776 |  | 61,776
Total comprehensive income for the year |  | - |  | 61,776 |  | 61,776
Dividends |  |  |  | (38,000) |  | (38,000)
Total investments by and distributions to owners |  | - |  | (38,000) |  | (38,000)
At 31 March 2023 |  | 1,000 |  | 72,453 |  | 73,453
5

Index Microbiology Limited Notes to the Financial Statements For the year ended 31 March 2023
General Information Index Microbiology Limited is a private company, limited by shares, registered in England and Wales, registration number 08261589, registration address The Churchill Building, University Of Bristol, Langford, Bristol, BS40 5DU. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard) Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Government grants Grants towards capital expenditure are released to the income statement over the expected useful life of the assets. Grants received towards revenue expenditure are released to the income statement as the related expenditure is incurred. Operating lease rentals Rentals payable under operating leases are charged against income on a straight line basis over the lease term. Taxation Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Current and deferred tax assets and liabilities are not discounted Deferred taxation Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the reporting date. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Current and deferred tax assets and liabilities are not discounted. Intangible assets Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable. Licences and patents Licences and patents are stated at cost less amortisation. Amortisation of licences is calculated on a straight line basis over the life of the licence. Amortisation of patents is calculated on a straight line basis over the estimated expected useful economic life of the patents of 5 years. Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Plant and Machinery | 20% Reducing Balance
Provisions Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.
2. | Average number of employees Average number of employees during the year was 5 (2022 : 4).
3. | Intangible fixed assets
Cost | Other |  | Total
| £ |  | £
At 01 April 2022 | 15,189 |  | 15,189
Additions | - |  | -
Disposals | - |  | -
At 31 March 2023 | 15,189 |  | 15,189
Amortisation
At 01 April 2022 | 10,731 |  | 10,731
Charge for year | 1,115 |  | 1,115
On disposals | - |  | -
At 31 March 2023 | 11,846 |  | 11,846
Net book values
At 31 March 2023 | 3,343 |  | 3,343
At 31 March 2022 | 4,458 |  | 4,458
4. | Tangible fixed assets
Cost or valuation | Plant and Machinery |  | Total
| £ |  | £
At 01 April 2022 | 33,031 |  | 33,031
Additions | 6,687 |  | 6,687
Disposals | - |  | -
At 31 March 2023 | 39,718 |  | 39,718
Depreciation
At 01 April 2022 | 21,376 |  | 21,376
Charge for year | 3,402 |  | 3,402
On disposals | - |  | -
At 31 March 2023 | 24,778 |  | 24,778
Net book values
Closing balance as at 31 March 2023 | 14,940 |  | 14,940
Opening balance as at 01 April 2022 | 11,655 |  | 11,655
5. | Debtors: amounts falling due within one year
| 2023 £ |  | 2022 £
--- | --- | --- | ---
Trade Debtors | 52,215 |  | 49,296
Prepayments & Accrued Income | 32,012 |  | 25,812
Other Debtors | 829 |  | 829
| 85,056 |  | 75,937
6. | Creditors: amount falling due within one year
| 2023 £ |  | 2022 £
--- | --- | --- | ---
Trade Creditors | 18,898 |  | 17,973
Bank Loans & Overdrafts | 2,949 |  | 2,949
Corporation Tax | 13,459 |  | 8,386
PAYE & Social Security | 1,857 |  | 2,848
Accrued Expenses | 12,332 |  | 1,420
Other Creditors | 386 |  | 2,854
Directors' Current Accounts | 4 |  | 2,600
VAT | 9,747 |  | 10,019
| 59,632 |  | 49,049
7. | Creditors: amount falling due after more than one year
| 2023 £ |  | 2022 £
--- | --- | --- | ---
Bank Loans & Overdrafts | 7,539 |  | 10,536
| 7,539 |  | 10,536
8. | Provisions for liabilities
| 2023 £ |  | 2022 £
--- | --- | --- | ---
Deferred Tax | 2,839 |  | 3,062
| 2,839 |  | 3,062
6